Suppr超能文献

Sortase-A 介导的单域抗体化学酶脂质化用于细胞膜工程。

Sortase-A mediated chemoenzymatic lipidation of single-domain antibodies for cell membrane engineering.

机构信息

Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany.

BioMed X GmbH, Im Neuenheimer Feld 583, 69120 Heidelberg, Germany.

出版信息

Eur J Pharm Biopharm. 2020 Aug;153:121-129. doi: 10.1016/j.ejpb.2020.05.019. Epub 2020 May 28.

Abstract

PURPOSE

Membrane engineering has versatile applications in adoptive cell therapies, immune therapy or drug delivery. Incorporation of lipidated antibody-derived ligands into cells may enforce supraphysiological cell interactions that offer new therapeutic approaches. A challenge is the defined synthesis of lipidated ligands that effectively interact with such membranes.

METHODS

Sortase-A was used to attach a PEGylated, dimyristyl lipid-anchor on single-domain antibodies (VHH). The membrane insertion was investigated on liposomal bilayers, myeloid-derived suppressor cells (MDSC) and T cells.

RESULTS

The lipidated VHHs remodeled liposomal as well as cellular membranes. The VHH carrying liposomes were successfully targeted towards antigen-positive cells. MDSC and T cells were both modified with lipidated VHHs as detected with an FITC-anti-llama antibody. T cells that carried an anti-CD11b VHH showed cellular association in vitro with CD11bGr-1 MDSC in a two-dimensional magnetic activated cell sorting / flow-cytometry assay.

CONCLUSION

The applied combination of chemoenzymatic ligation, PEGylated lipid anchors and single-domain antibodies delivers water-soluble and chemically defined lipidated ligands, which readily associate with liposomal and cellular membranes. This enables liposomal drug targeting and artificial cell-cell interactions. Hence, the presented concept for lipidation of single-domain antibodies is promising for further application in the field of drug delivery or cell-based therapies.

摘要

目的

膜工程在过继细胞疗法、免疫疗法或药物传递中有多种应用。将脂质化的抗体衍生配体掺入细胞中可以增强超生理细胞相互作用,提供新的治疗方法。挑战在于定义合成能够有效与这些膜相互作用的脂质化配体。

方法

使用 Sortase-A 将聚乙二醇化的二肉豆蔻酰脂质锚定在单域抗体 (VHH) 上。在脂质体双层、髓样来源的抑制细胞 (MDSC) 和 T 细胞上研究了膜插入情况。

结果

脂质化的 VHH 重塑了脂质体和细胞膜。携带脂质体的 VHH 成功靶向抗原阳性细胞。用 FITC-抗羊驼抗体检测到脂质化 VHH 修饰了 MDSC 和 T 细胞。携带抗 CD11b VHH 的 T 细胞在二维磁激活细胞分选/流式细胞术测定中与 CD11bGr-1 MDSC 表现出细胞相关性。

结论

化学酶结合、聚乙二醇化脂质锚和单域抗体的应用组合提供了水溶性和化学定义的脂质化配体,可轻易与脂质体和细胞膜结合。这使得脂质体药物靶向和人工细胞-细胞相互作用成为可能。因此,所提出的单域抗体脂质化概念有望在药物传递或基于细胞的治疗领域得到进一步应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验